We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial.
- Authors
Shah, Viral N.; Al‐Karadsheh, Amer; Barnes, Cathy; Mandry, Jose; Nakhle, Samer; Wernicke‐Panten, Karin; Kramer, Daniel; Schmider, Wolfgang; Pierre, Suzanne; Teichert, Lenore; Rotthaeuser, Baerbel; Mukherjee, Bhaswati; Bailey, Timothy S.
- Abstract
Aim: To assess whether multiple switches between SAR341402 biosimilar insulin aspart (SAR‐Asp) and the insulin aspart reference product (NovoLog; NN‐Asp) leads to equivalent pharmacokinetic (PK) exposure compared with continuous use of NN‐Asp in adults with type 1 diabetes (T1D). Materials and Methods: This multicentre, open‐label, phase 3 study randomized (1:1) 210 subjects with T1D treated with once‐daily insulin glargine U100 as basal insulin to four 4‐week periods of alternating multiple daily injections of SAR‐Asp and NN‐Asp (NN‐Asp for the first 4 weeks, SAR‐Asp in the last 4 weeks; switching group) versus 16 weeks of continuous NN‐Asp (non‐switching group). At week 16, a single dose (0.15 U/kg) of SAR‐Asp in the switching group (n = 95) or NN‐Asp in the non‐switching group (n = 105) was given in the morning before breakfast. Primary PK endpoints were area under the plasma concentration curve (AUC) and maximum plasma concentration (Cmax) of SAR‐Asp versus NN‐Asp after the single dose at week 16. Results: The extent of PK exposure was similar between the two treatments (SAR‐Asp in the switching group and NN‐Asp in the non‐switching group) at week 16, with point estimates of treatment ratios close to 1. The 90% confidence intervals for AUC treatment ratios were contained within 0.8‐1.25. For Cmax in the primary analysis set, the upper confidence limit was 1.32. This was because of the profiles of three participants with implausible high values. A prespecified sensitivity analysis excluding implausible values showed results contained within 0.8‐1.25. Conclusions: PK exposure of SAR‐Asp (switching group) and reference NN‐Asp (non‐switching group) were similar, supporting interchangeability between these two insulin aspart products.
- Subjects
INSULIN aspart; TYPE 1 diabetes; PHARMACOKINETICS; CONFIDENCE intervals
- Publication
Diabetes, Obesity & Metabolism, 2024, Vol 26, Issue 2, p540
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.15341